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ABSTRACT
P-TEFb regulates eukaryotic gene expression at
the level of transcription elongation, and is itself
controlled by the reversible association of 7SK RNA
and an RNA-binding protein HEXIM1 or HEXIM2.
In an effort to determine the minimal region of 7SK
needed to interact with HEXIM1 in vitro, we found
that an oligo comprised of nucleotides 10–48
sufficed. A bid to further narrow down the minimal
region of 7SK led to a surprising finding
that HEXIM1 binds to double-stranded RNA in a
sequence-independent manner. Both dsRNA and
7SK (10–48), but not dsDNA, competed efficiently
with full-length 7SK for HEXIM1 binding in vitro.
Upon binding dsRNA, a large conformational
change was observed in HEXIM1 that allowed
the recruitment and inhibition of P-TEFb. Both
subcellular fractionation and immunofluorescence
demonstrated that, while most HEXIM1 is found in
the nucleus, a significant fraction is found in the
cytoplasm. Immunoprecipitation experiments
demonstrated that both nuclear and cytoplasmic
HEXIM1 is associated with RNA. Interestingly, the
one microRNA examined (mir-16) was found in
HEXIM1 immunoprecipitates, while the small
nuclear RNAs, U6 and U2, were not. Our study
illuminates novel properties of HEXIM1 both in vitro
and in vivo, and suggests that HEXIM1 may
be involved in other nuclear and cytoplasmic
processes besides controlling P-TEFb.
INTRODUCTION
P-TEFb plays a key role in RNA polymerase II
elongation control (1–3). It is comprised of one of two
isoforms of Cdk9 (4,5) and one of three cyclins, T1, T2 (6)
or K (7) in humans. One of the major targets of the kinase
activity of P-TEFb is the carboxyl-terminal domain
(CTD) of the largest subunit of RNA polymerase II (8),
and this phosphorylation of the CTD by P-TEFb
occurs during transcription elongation (9). P-TEFb also
phosphorylates the negative transcription elongation
factor DSIF (10), turning it into a positive elonga-
tion factor (11). P-TEFb controls gene expression by
regulating the fraction of RNA polymerase II molecules
that generate full-length mRNAs. In addition to its
normal cellular role, P-TEFb has been shown to be
recruited by viral transactivator Tat to the nascent viral
transcript, TAR, near the promoter to enhance viral
transcription, which is required for eﬃcient HIV-1
replication (4,12–16).
P-TEFb is uniquely regulated by the reversible associa-
tion of a small nuclear RNA, 7SK (17,18) and one of two
HEXIM proteins (19–22). Glycerol gradient analyses of
cell lysates indicate that two forms of P-TEFb exist in the
cell. An active form of P-TEFb, free of HEXIM and 7SK,
interacts with a variety of cellular factors, including
NF-kB (16), c-Myc (23,24), MyoD (25) and Brd4 (26,27),
to regulate gene transcription. A larger, inactive form
contains 7SK and HEXIM proteins that together
sequester active P-TEFb (17,19,22). When cells are treated
with P-TEFb inhibitors, such as DRB, or other agents
that block transcription, P-TEFb is quickly released from
the large form (19). This form of P-TEFb regulation is
physiologically signiﬁcant, because it has been shown that
all signals that trigger cardiac hypertrophy converge at the
critical step of activating P-TEFb through the dissociation
of 7SK and HEXIM. This activation causes increased
cellular transcription and an increase in the size of
cardiomyocytes (28–31). Factors that release P-TEFb
from the 7SK HEXIM1 P-TEFb complex are currently
unknown.
Several studies have uncovered some of the important
interactions in the 7SK HEXIM1 P-TEFb complex.
Functional domains of HEXIM1 have been identiﬁed.
The N-terminal region of HEXIM1 (amino acids 1–120) is
found to be self-inhibitory, preventing HEXIM1 from
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The region centered upon KHRR (amino acids 152–155)
is involved in the binding of 7SK, and nearby sequences
comprise nuclear localization signals (33,34). An adjacent
region centered upon PYNT (amino acids 202–205) is
involved in interaction with P-TEFb (33), and a small
region centered upon Y271 is involved in inhibition of
P-TEFb (32). The C-terminal region of HEXIM1
(amino acids 281–359) mediates the dimerization of
HEXIM1 via a leucine zipper motif (21,32,35,36). In
addition, the regions involved in interactions have been
narrowed down to amino acids 1–254 of 726 of cyclin T1,
all of Cdk9 and nucleotide 1–172 of 7SK (32,33).
Furthermore, phosphorylation of the T-loop of Cdk9
has been implicated in the activation of P-TEFb and is
required for the formation of the 7SK HEXIM1 P-TEFb
complex (32,37).
In attempts to narrow down the minimal sequence of
7SK that is needed to form the 7SK HEXIM1 P-TEFb
complex in vitro, we serendipitously discovered that
HEXIM1 is a potent dsRNA-binding protein. Further
analysis revealed that dsRNA induces a conformational
change in HEXIM1, so that it can interact with P-TEFb.
In addition, in vivo studies demonstrated that endogenous
HEXIM1 can be found in both the cytoplasm and
nucleus, and most HEXIM1 in cells is associated with a
variety of RNAs. Interestingly, at least one microRNA
was found to be associated with HEXIM1. These ﬁndings
provide a mechanistic insight into the inhibition of
P-TEFb by HEXIM1 and RNA, suggest a possible
mechanism on how cells balance active and inactive
forms of P-TEFb and indicate that HEXIM1 may play
other roles besides inhibiting P-TEFb in vivo.
MATERIALS AND METHODS
EMSA
Here, 12ml reactions were carried out in 25mM HEPES,
pH 7.6, 15% glycerol, 60mM KCl, 0.1mM EDTA, 5mM
DTT, 0.01% NP-40 and included 200ng recombinant
HEXIM1, recombinant P-TEFb and various RNA
or DNA oligos as indicated. Reactions were incubated
at room temperature for 15min and resolved on
a 6% polyacrylamide (19:1 acrylamide:bis-acrylamide
ratio) gel in 0.5  Tris glycine at 48C for 1.5h at 6W.
unless otherwise indicated. Proteins were visualized by
silver staining.
Tryptophanfluorescence emission spectra
Tryptophan ﬂuorescence studies were performed on a
Fluorolog 3 spectroﬂuorimeter (Jobin Yvon, Horiba) with
a 450-W xenon lamp using 4 and 8nm excitation and
emmision bandpasses, respectively. All spectra were taken
under identical buﬀer conditions as used in EMSAs at
258C. Emission spectra of 1mM HEXIM1 were obtained
using a constant excitation wavelength of 276nm and,
monitoring the resultant ﬂuorescent intensity between 290
and 450nm, emission spectra of 1mM HEXIM1 in the
presence of dsDNA or dsRNA were obtained using
identical instrument conditions as HEXIM1 alone.
HEXIM1 data were not corrected for contributions
from the buﬀer or dsDNA/dsRNA, as scans of these
components under conditions identical to those described
above indicated a negligible contribution to the emission
spectra.
Purification of P-TEFb
Baculoviruses expressing human Cdk9 and cyclin T1
(1–290) were generated using the BaculoDirect
Baculovirus Expression System (Invitrogen) according to
the manufacturer’s instructions. Cdk9 was tagged with six
histidines at its carboxyl terminus, and cyclin T1 was
untagged. Sf9 cells were maintained suspended in Sf-900 II
serum-free medium (SFM) (Invitrogen) at concentrations
between 5 10
5 and 2 10
6 cells/ml. Here, 10ml of a third
ampliﬁcation stock of each virus was added to 1liter of
cells (at 1 10
6 cells/ml) in a 2-l Erlenmeyer ﬂask, and the
cells were shaken at 100r.p.m. at 288C for 72h. Cells were
spun down at 1000 g, and the cell pellet was sonicated
(three 10-s bursts) in 10ml of Buﬀer L [10mM Tris (pH
8.0), 150mM NaCl, 2mM MgCl2, 1% Triton, 0.1% of a
saturated PMSF isopropanol solution, 1  EDTA-free
protease inhibitor mixture (Roche Applied Science)
and 10mg/ml E-64 protease inhibitor (Roche Applied
Science)]. The cell lysate was spun for 15min at 192000g
in a Beckman tabletop centrifuge. The supernatant
was then incubated with 1ml of nickel-nitrilotriacetic
acid resin (Qiagen) for 45min at 48C. The resin was
washed once with 10ml of Buﬀer L, followed by a wash
with 1ml of 10mM Tris (pH 8.0), 500mM NaCl, 1%
Triton, 0.1% of a saturated PMSF isopropanol solution
and 25mM imidazole and with 10ml of 60mM HGKEP.
P-TEFb was eluted with 2.5ml of 60mM HGKEP
with 300mM imidazole and loaded onto a 1-ml Mono
S column. P-TEFb was eluted with a 20-ml linear gradient
from 0.1 to 0.5M HGKEDP.
Kinase assay
Here, 16ml kinase reactions containing puriﬁed recombi-
nant P-TEFb with human DSIF as the substrate were
carried out in 30mM KCl, 20mM HEPES pH 7.6, 7mM
MgCl2,3 0mM ATP, 1.3mCi of [g-
32P]-ATP (Amersham),
1mg BSA per reaction and the indicated amounts of
HEXIM1 proteins. T7-transcribed 7SK RNA or RNA
oligos was added last to the pre-incubation. All reactions
were incubated for 10min at 238C prior to the addition of
ATP. The kinase reactions were then incubated for 20min
at 308C and then stopped by the addition of SDS-PAGE
loading buﬀer. Reactions were resolved by 9%
SDS-PAGE. The dried gel was subjected to autoradiog-
raphy and quantiﬁed with a Packard InstantImager.
Glycerol gradient analysis
HeLaS3 cells, at 90% conﬂuency in a T-75 ﬂask, were
scraped, spun down at 2000r.p.m. and then lysed for
10min on ice in 150mM NaCl, 2mM MgCl2,1 0 m M
HEPES, 1mM EDTA, 1mM DTT, 1% PMSF,
EDTA-free complete protease inhibitor cocktail (Roche)
and 0.5% NP-40, and the lysates were clariﬁed
by centrifugation for 10min at 14000r.p.m. prior to
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the same buﬀer conditions used during lysis, except that
NP-40 was omitted. Gradients were run at 45000r.p.m.
for 16h in a Beckman SW-Ti55 rotor before being
fractionated.
Native gel analysis of HEXIM1 incell extracts
Cell extracts were separated on a 6% polyacryl-
amide (19:1 acrylamide:bis-acrylamide ratio) gel in
0.5  Tris glycine at 48C for 1.5h at 6W, followed by
transfer to BA85 PROT membrane (Whatman). HEXIM1
was then detected by western blotting analysis, as
described below. For RNase treatment, 100ng RNase A
(Fermentas) was incubated with cell extracts or glycerol
gradient fractions for 10min at 308C. Total reactions were
then examined by native gel analysis, as described above.
Immunofluorescence
HeLa cells were grown on glass coverslips, ﬁxed for 20min
in 4% paraformaldehyde/PBS. Cells were permeabilized
with 0.5% Triton-X 100 in PBS for 5min and washed in
PBS. After being blocked in 2% donkey serum in PBS
for 15min, cells were incubated with aﬃnity-puriﬁed,
anti-HEXIM1 antibodies (Abcam ab28016) in blocking
solution. After washing in PBS four times, cells
were incubated in a 1:200 dilution of Alexa Fluor 647
donkey-anti-sheep IgG (Molecular Probes) secondary
antibody for 2h. To visualize DNA, cells were stained
with 0.5mg/ml of DAPI after secondary antibody incuba-
tion. All incubations were at room temperature. After
washing in PBS, coverslips were mounted in Prolong
Antifade mounting medium (Molecular Probes) and cells
were visualized with a Leica DMR microscope for each
ﬂuorochrome.
Cell fractionation
HeLa cells conﬂuent in four T-150 ﬂasks were pelleted and
washed once in ice-cold PBS, 0.1% PMSF. Cells were
resuspended in 2ml of cold buﬀer A [10mM HEPES,
15mM KCl, 2mM MgCl2, 0.1mM EDTA, 1mM DTT,
0.1% PMSF, 40U/ml RNaseOUT (Invitrogen)] and
lysed by homogenization in a 7-ml Dounce all-glass
homogenizer with a tight pestle using 15 strokes. Cell
lysates were spun for 5min at 4000r.p.m. at 48Ci na
microcentrifuge to separate cytoplasm from nuclei. Nuclei
were resuspended with 2ml of cold buﬀer B [10mM
HEPES, 2mM MgCl2, 0.5mM EDTA, 1mM DTT,
150mM NaCl, 0.5% NP-40, 0.1% PMSF, 40U/ml
RNaseOUT (Invitrogen)] and incubated on ice for
10min with occasional gentle votexing. Both cytoplasm
and nuclei extract were further spun for 10min at
65000r.p.m. in a 100.2-Ti rotor in a Beckman tabletop
centrifuge. Cleared lysates were used for western blot
analysis and saved at  808C.
Northern and western blot analysis
Total RNAs were extracted from individual glycerol
gradient fractions using mirVana miRNA isolation kit
(Ambion). The probe for 7SK was 50 end labeled using
T4 PNK (NEB), following manufacturer’s instructions.
RNAs were separated on a 6% denaturing gel and
transferred to a Nytran N membrane (Whatman) using
a semi-dry blotting apparatus. The membrane was
blocked with ULTRAhyb (Ambion) and probed
with labeled 7SK oligo, following the manufacturer’s
instruction. The washed membrane was exposed to ﬁlm
at  808C for 30min. The probe for 7SK was as follows
(numbers in parenthesis indicate the regions to which the
probes hybridize):
7SK (121–160): GGGGAUGGUCGUCCUCUUCG
ACCGAGCGCGCAGCUUCGGG
U6 (60–99): GGAACGCUUCACGAAUUUGCGUG
UCAUCCUUGCGCAGGGG
U2 (97–136): CGGAGCAAGCUCCUAUUCCAUCU
CCCUGCUCCAAAAAUCC
Mir-16-1: CGCCAAUAUUUACGUGCUGCUAAG
GCACUGCUGAC
Western blots were carried out as previously
described (22).
RESULTS
7SK(10–48) issufficient to bindHEXIM1
While studies have been carried out to map interaction
domains of HEXIM1 and P-TEFb in the large, inactive
7SK HEXIM P-TEFb complex, further reﬁnement of the
regions of 7SK required to form this complex are needed.
Because HIV Tat protein and HEXIM1 have a nearly
identical RNA-binding motif (33,34), we looked for
regions of 7SK that might mimic the Tat-binding site
(TAR) in the HIV 50 UTR. Tat binds a bulged region of
TAR RNA containing the sequence AUCUG.
Considering that AUCUG should appear randomly only
once in every 1024nt, we were surprised to ﬁnd that 7SK
(330nt) contained three AUCUG motifs in the ﬁrst 70nt.
The ﬁrst two reside in nucleotides 10–48 (Figure 1A).
In addition, mFold analysis (Figure 1B) suggested that the
structure of the ﬁrst AUCUG in the context of nucleotides
10–48 resembled that predicted to occur in TAR (data not
shown). These observations prompted us to test if 7SK
(10–48) was able to bind HEXIM1 using a modiﬁed
electrophoretic mobility shift assay (EMSA). In this assay,
recombinant HEXIM1 was examined on a native gel
and visualized by silver staining. As shown in Figure 1C,
wild-type HEXIM1 (WT) migrated as a discrete band as
expected (32) for a dimer of HEXIM1. When increasing
amounts of the 7SK oligo were added, HEXIM1 shifted
up the gel to a new discrete position. The shift was
complete when 10pmol of the oligo were added.
Moreover, no further signiﬁcant shift occurred in the
presence of excess oligo up to 100pmol. Because the
reactions contained 5pmol of HEXIM1 and a little more
than 50% of the HEXIM1 was shifted by 3pmol of
the 7SK oligo, it is likely that, similar to what was
found earlier with 7SK (32), a one-to-one complex of
RNA to HEXIM1 dimer formed. As a control,
HEXIM1 containing a substitution of ILAA for KHRR
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was analyzed. Addition of the 7SK oligo did not result in
any speciﬁc shift of the mutant HEXIM1. These results
indicate that the 39-nt oligo binds to HEXIM1 and that
this binding requires the same region of HEXIM1 needed
for binding to 7SK.
HEXIM1binds double-stranded but notsingle-stranded
nucleicacid
A set of RNA oligos were then designed to further narrow
down the region of 7SK required for HEXIM1 interaction
in vitro. These oligos contain either individual AUCUG
regions or other regions of 7SK as negative controls
(Figure 1D). The ability of these oligos to bind HEXIM1
was analyzed in EMSA (raw data not shown). To our
surprise, none of these oligos changed the mobility of
HEXIM1, except for one of the negative controls, 7SK
(303–319), which does not have the AUCUG sequence. It
showed only a weak interaction. mFold analyses of these
ﬁve oligos revealed that there was a correlation not with
the presence of AUCUG, but rather the stability of
potential double-stranded stem structures (Figure 1D).
This observation prompted us to ask if HEXIM1 actually
binds to a double-stranded structure. First, we tested a set
of siRNA oligos used to knock down cellular genes. They
had double-stranded regions of either 19 or 25bp with two
deoxynucleotide overhangs at one or both 30 ends and did
not share any sequence similarities with each other or
7SK. Remarkably, all of them were able to shift HEXIM1
as well as the 7SK (10–48) oligo (data not shown). Again,
all of them failed to shift the ILAA HEXIM1 mutant, a
7SK-binding-deﬁcient HEXIM1 mutant (data not shown).
These data suggested that HEXIM1 could associate with
dsRNA, regardless of its sequence.
To eliminate the possibility that HEXIM1 required the
deoxynucleotide overhangs present in those siRNA
constructs, two 25-base single-stranded DNA oligos,
D1 and D2, and two single-stranded RNA oligos, R1
and R2, were designed. D1 has the same sequence
as R1 and is complementary to D2. Thus, we could
form one dsDNA (D1/D2), one dsRNA (R1/R2) and
two DNA/RNA hybrids (D1/R2 and D2/R1). When
single-stranded oligos (D1, D2, R1 and R2) were used,
none of them were able to shift HEXIM1 mobility
signiﬁcantly (Figure 2A). R1 was able to partially shift
HEXIM1at the highest concentration because it could
form a semi-stable double-stranded structure (data not
shown). In sharp contrast, when double-stranded oligos
were used, all of them were able to shift HEXIM1.
The only diﬀerence detected in this assay was that
the dsDNA HEXIM1 complex migrated diﬀerently
from the dsRNA HEXIM1 and DNA/RNA HEXIM1
complexes (Figure 2B). The diﬀerence in mobility between
dsRNA HEXIM1 and dsDNA HEXIM1 will be
addressed later.
Because it is possible that the mobility of HEXIM1
might not change upon binding a short oligo, the potential
binding was assayed using the shift of labeled oligos. The
conditions were identical to those used in preceding
EMSAs, except that the R2 oligo was 50 end labeled to
low speciﬁc activity. WT and ILAA HEXIM1 (2pmol)
were incubated with increasing amounts of either
R2 (ssRNA) or R1/R2 (dsRNA). HEXIM1 was visualized
by silver staining. As expected, dsRNA lowered the
mobility of WT HEXIM1 but not that of the ILAA
RNA-binding mutant (Figure 2C, top panel). Note that
the HEXIM1 shift was less dramatic than that seen earlier
because the native gel was stopped very early to keep the
small RNAs from running oﬀ the gel. ssRNA failed to
slow the mobility of either WT or ILAA (Figure 2C, top
panel). Autoradiography of the region of the gel
containing the HEXIM1 proteins demonstrated that
only dsRNA was associated with HEXIM1 (Figure 2C,
middle panel). This binding was saturated at  3pmol
of dsRNA. Autoradiography of the bottom of the gel
(same exposure as the middle panel) conﬁrmed that
dsRNA, but not ssRNA, was binding. The unbound
labeled dsRNA was only seen after binding to HEXIM1
was saturated (Figure 2C, lower panel). We conclude that
HEXIM1 binds stoichiometrically to dsRNA, but does
not bind to ssRNA.
dsRNA butnot dsDNA can competeefficiently with 7SKfor
HEXIM1 binding
Because 7SK (10–48), dsDNA and dsRNA bind the same
region of HEXIM1 as 7SK does, we examined the relative
binding strength of 7SK (10–48), dsDNA, dsRNA and
Figure 1. 7SK (10–48) oligo interacts with HEXIM1. (A) The sequence
of 7SK (10–48) oligo containing two AUCUG. (B) The predicted
structure of 7SK (10–48) by mFold. (C) EMSA analysis of wild-type
(WT) and ILAA mutant HEXIM1 proteins with 7SK (10–48) of
indicated amount. Here, 5pmol of WT or ILAA was used in each lane,
and the 6% gel was silver stained. (D) Sequence and binding aﬃnity of
oligos tested in EMSA. (E) The predicted structures of 7SK (19–35),
(57–73), (303–319) by mFold.
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tion of 1pmol of 7SK lowered the mobility of 0.5pmol of
HEXIM1 (Figure 3A). When the binding reaction
contained 1pmol of 7SK and increasing amounts of
dsDNA, the 7SK HEXIM1 complex was unaﬀected at 0.5
and 5pmol, and was only partially decreased at 50pmol of
dsDNA (Figure 3A). In sharp contrast, both dsRNA and
7SK (10–48) were able to compete eﬃciently with 7SK to
form dsRNA HEXIM1 and 7SK (10–48) HEXIM1
complexes, respectively (Figure 3A).
Further evidence that dsRNA has a higher aﬃnity to
HEXIM1 than dsDNA came from the direct competition
between the two. Previously, we reported that the
7SK HEXIM1 complex is relatively stable because
32P-labeled 7SK in a pre-formed 7SK HEXIM1 complex
could not be competed oﬀ by the addition of cold 7SK
even at 100-fold excess (33). Because of this, an experi-
ment was designed to look at competition for HEXIM1
binding under two conditions. DNA and RNA
were mixed together before HEXIM1 was added to look
at competition during binding, or DNA or RNA were
added separately to allow prebinding to HEXIM1
before the other was added. When the binding reaction
contained 0.5pmol of dsRNA and increasing amounts
of dsDNA were added to HEXIM1at the same
time, only dsRNA HEXIM1 was detected (Figure 3B,
dsDNA During). To examine the stability of the
dsRNA HEXIM1 complex, we preformed this complex
and then added increasing amount of dsDNA. Even a
10-fold excess of dsDNA was unable to aﬀect the
dsRNA HEXIM1 complex (Figure 3B, dsDNA After).
This protocol was repeated using a constant amount of
dsDNA and increasing amounts of dsRNA. Again,
dsRNA was able to eﬃciently compete with dsDNA
binding to HEXIM1, even if the dsDNA complex was
preformed before dsRNA addition (Figure 3C). Taking
into consideration the concentration of the various nucleic
acids used, dsRNA, 7SK (10–48) and 7SK had roughly
equal aﬃnity for HEXIM1, while dsDNA had  1% of
that aﬃnity.
dsRNAbinding induces changes in intrinsic tryptophan
fluorescence of HEXIM1
The shift to lower mobility upon binding of 25-bp dsRNA
(16kDa) to HEXIM1 (80kDa dimer) was somewhat
unexpected, especially considering that the overall nega-
tive charge of the dsRNA HEXIM1 complex was
increased signiﬁcantly, which would tend to increase its
mobility. We reasoned that the binding of dsRNA might
induce a conformational change in HEXIM1, leading to a
decrease in mobility due to its more expanded shape. In an
attempt to obtain further evidence for a conformational
change in HEXIM1 induced by dsRNA, intrinsic ﬂuores-
cence from tryptophan residues was measured. Using
1mM HEXIM1 in a buﬀer identical to that used in the
EMSA, the optimal excitation wavelength was found to be
276, nm and this provided a strong peak in emission at
350.7nm (Figure 4A). An equimolar amount of dsDNA
or dsRNA in the same buﬀer had negligible emission (data
not shown). When 1mM of dsDNA was added to the
HEXIM1 solution, a 10% reduction in the emission signal
was detected, and the peak in emission remained at
essentially the same wavelength (350.8nm). In contrast,
Figure 2. HEXIM1 interacts with double-stranded, but not single-
stranded nucleic acids. (A) EMSA analysis of HEXIM1 with single-
stranded DNA (D1, D2) and single-stranded RNA (R1, R2). Each lane
contains 5pmol of wild-type HEXIM1. (B) EMSA analysis of
HEXIM1 (silver stain) with double-stranded DNA (D1/D2), DNA/
RNA hybrids (D1/R2, D2/R1) and double-stranded RNA (R1/R2).
Each lane contains 5pmol of wild-type HEXIM1. (C) EMSA analysis
of wild-type and ILAA mutant HEXIM1proteins with labeled single-
stranded RNA (ssRNA) and double-stranded RNA (dsRNA).
Each lane contains 2pmol of wild-type or ILAA mutant HEXIM1
proteins. The top panel is a silver-stained gel showing the region
containing HEXIM1, the middle panel is an autoradiograph of the
same region and the bottom panel is an autoradiograph (same exposure
as the middle panel) of the bottom of the gel where free-labeled
probes run.
Figure 3. 7SK, dsRNA and 7SK (10–48) have higher aﬃnity than
dsDNA for HEXIM1 binding. (A) Competition of 7SK HEXIM1
interaction by dsDNA, dsRNA or 7SK (10–48) oligo analyzed by
EMSA (silver-stained gel). Each lane contains 0.5pmol of wild-type
HEXIM1. (B) Competition of dsRNA HEXIM1 interaction by
dsRNA analyzed by EMSA. Each lane contains 0.5pmol of wild-type
HEXIM1 (silver-stained gel). (C) Competition of dsDNA HEXIM1
interaction by dsDNA analyzed by EMSA. Each lane contains 0.5pmol
of wild-type HEXIM1 (silver-stained gel).
Nucleic Acids Research, 2007, Vol. 35, No. 8 2507the addition of 1mM dsRNA decreased the emission signal
to 50%, and shifted the peak in emission to 352.0nm.
Diﬀerences in the normalized spectra conﬁrmed that
dsRNA, but not DNA, caused a shift in the max as
evidenced by the inversion in sign of the diﬀerence at
around 350nm (Figure 4B). We do not know why RNA
additionally caused a peak at 299nm in the diﬀerence
spectrum, but DNA did not cause any change. Both the
large decrease in intrinsic ﬂuorescence, the observed
changes in the diﬀerence spectrum and a shift of the
emission peak are consistent with an RNA-induced
change in conformation, in which one or more of
the four tryptophan residues moves from a relatively
hydrophobic to a more hydrophilic environment.
dsRNA HEXIM1 can recruit and inhibit P-TEFb in vitro
Next, we determined if dsRNA HEXIM1 could interact
with P-TEFb by EMSA. P-TEFb containing full-length
Cdk9 and truncated cyclin T1 with amino acids 1–290
was expressed in a baculovirus system and puriﬁed.
The ﬁnal product had no detectable contaminants even
when examined on an overloaded, silver-stained SDS gel
(Figure 5A). When HEXIM1 and P-TEFb were mixed
together and examined by EMSA, there was no detectable
intermediate band (Figure 5B), indicating HEXIM1 does
not directly interact with P-TEFb. This is in agreement
with previous ﬁndings that HEXIM1 does not interact
with P-TEFb without 7SK (32,33). However, when
dsRNA was added, free P-TEFb disappeared, while
a new band formed above the dsRNA HEXIM1 band,
demonstrating that P-TEFb was recruited to form
a dsRNA HEXIM1 P-TEFb complex (Figure 5B).
Similar results were obtained with P-TEFb containing
full-length cyclin T1 (data not shown). A kinase assay
was then used to examine the eﬀect of dsRNA on
P-TEFb activity. As expected, HEXIM1, 7SK, dsRNA
and dsDNA by themselves did not alter the kinase
activity of P-TEFb. Both the 7SK HEXIM1 and
dsRNA HEXIM1 complexes dramatically inhibited the
kinase activity of P-TEFb, which is unchanged in the
presence of the dsDNA HEXIM1 complex (Figure 5C).
This is in agreement with earlier results showing that both
7SK and dsRNA but not dsDNA can induce a
conformational change in HEXIM1, resulting in the
recruitment of P-TEFb.
Most endogenous HEXIM1 associates withRNAs in vivo
Because the dsRNA HEXIM1 interaction is independent
of the sequence of dsRNA in vitro, and up to 80% of
endogenous HEXIM1 is not in complex with 7SK in HeLa
cells (22), we set out to determine if HEXIM1 is associated
with other cellular RNAs besides 7SK. HeLa cells were
lysed in the presence of a non-ionic detergent, and
the lysate analyzed by glycerol gradient sedimentation.
In agreement with previous studies (22), most endogenous
HEXIM1 sedimented in fractions free of P-TEFb and
7SK (fractions 2–6, Figure 6A), and only a small fraction
of total HEXIM1 co-migrated with P-TEFb and 7SK
(fractions 8–11, Figure 6A). Glycerol gradient fractions
2–5 and 8–10 were then examined by native gel electro-
phoresis, followed by western blot analysis using an
aﬃnity-puriﬁed, anti-HEXIM1 antibody (Figure 6B).
While most HEXIM1 in fraction 2 migrated like the
recombinant HEXIM1, almost all HEXIM1 proteins in
the rest of the fractions examined had reduced mobility,
indicating that there were other components associated
with HEXIM1. Remarkably, when individual fractions
were treated with RNase A ﬁrst and then examined in the
same way, all HEXIM1 signals were compressed into a
single band that migrated like recombinant HEXIM1
Figure 4. dsRNA binding induces changes in intrinsic tryptophan
ﬂuorescence of HEXIM1. (A) Emission spectra of HEXIM1 were
obtained using a constant excitation wavelength of 276nm and
monitoring the resultant ﬂuorescent intensity between 290 and
450nm. Emission spectra of HEXIM1 in the presence of dsDNA or
dsRNA were obtained using identical instrument conditions as
HEXIM1 alone. (B) After normalization of the HEXIM1,
HEXIM1þdsDNA and HEXIM1þdsRNA spectra to 100%, the
diﬀerence spectra were calculated and plotted versus wavelength.
Figure 5. HEXIM1 dsRNA can recruit and inhibit P-TEFb. (A)
Puriﬁed recombinant P-TEFb containing full-length Cdk9 and cyclin
T1 (1–290) analyzed in a 9% SDS gel by silver staining. (B) EMSA
analysis of HEXIM1 and P-TEFb in the absence or presence of 2pmol
of dsRNA (silver-stained gel). Here, 2pmol of HEXIM1 and 4pmol of
P-TEFb were used. (C) The eﬀect of 7SK, dsRNA and dsDNA on P-
TEFb kinase activity in the absence or presence of HEXIM1 analyzed
by P-TEFb kinase assay using human DSIF as the substrate. Label is
incorporated into the large DSIF subunit (Spt5). 1 ¼0.15pmol. An
autoradiograph is shown.
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HEXIM1 is associated with RNAs.
The method used above to generate a HeLa cell lysate
utilized non-ionic detergent, resulting in the release of
HEXIM1, 7SK and most P-TEFb from the nucleus
(data not shown). This raised the possibility that
HEXIM1 RNA complexes observed above might be an
artifact of nuclear HEXIM1 interacting with cytoplasmic
RNAs. To examine this possibility, cells were lysed by
homogenization in the absence of detergent, followed by
diﬀerential centrifugation to separate nuclei from the
cytoplasm. The nuclei were then extracted in the presence
of a non-ionic detergent. As shown in Figure 7A, most if
not all Cdk9 was retained in the nucleus, demonstrating
successful separation of the cytoplasm from the nucleus.
Surprisingly, a considerable amount of HEXIM1 was
present in the cytoplasmic fraction. Both nuclear and
cytoplasmic HEXIM1 proteins were then examined by
native gel electrophoresis. While a small fraction of
nuclear HEXIM1 migrated the same as recombinant
HEXIM1, most nuclear HEXIM1 had reduced mobility
compared to free HEXIM1 (Figure 7B). Also, most, if not
all, cytoplasmic HEXIM1 had reduced mobility compared
to recombinant HEXIM1. Again, RNase A treatment
compressed virtually all HEXIM1 signals to a discrete
band (Figure 7B). Consistent with the biochemical
fractionation result (Figure 7A), immunoﬂuorescence
staining with aﬃnity-puriﬁed anti-HEXIM1 antibodies
demonstrated that most HEXIM1 was localized in the
nucleus, while a portion of HEXIM1 was detectable in
the cytoplasm (Figure 7C). Several previous studies used
immunoﬂuorescence to demonstrate that HEXIM1
was predominately nuclear (19,33,38). In those studies,
cytoplasmic staining was not visible or was visible and not
mentioned. The cytoplasmic localization seen here is
validated by analysis of background staining (Figure 7C,
secondary antibody alone) and by biochemical fractiona-
tion (Figure 7A). We conclude that the most endogenous
HEXIM1 is in the nucleus and that a signiﬁcant fraction is
present in the cytoplasm. Importantly, most HEXIM1,
regardless of location, is associated with RNA.
HEXIM1associates with microRNAs in vivo
Because microRNAs have extensive double-stranded
regions, we examined if HEXIM1 was associated with
microRNAs in vivo. HeLa cell extracts were incubated
with pre-immune serum immobilized on protein G beads.
RNA was extracted from an aliquot of ﬂowthrough,
and the rest was further incubated with aﬃnity-puriﬁed
anti-HEXIM1 antibodies immobilized on protein G
beads. RNA was extracted from the ﬂowthrough. After
an extensive wash, RNA was also extracted from the
bound material (Figure 7D). The fractions were analyzed
by northern blot using several probes. As expected, most
7SK, U2 and U6 RNAs were present in the ﬂowthrough
after incubation with pre-immune serum. In contrast,
Figure 6. Most endogenous HEXIM1 associates with RNA. (A) HeLa
cell extracts isolated in the presence of non-ionic detergent were
separated on a 5–45% linear glycerol gradient sedimentation, followed
by fractionation into 16 fractions. Protein components were visualized
by SDS PAGE followed by western blot analysis using antibodies
against the indicated proteins. Total RNA was extracted from an
aliquot of each fraction, and 7SK was visualized by northern blot
analysis. (B) Proteins in glycerol gradient fractions were treated with or
without RNase A, separated by native gel electrophoresis ﬁrst and then
HEXIM1 was visualized by western blot analysis. R¼recombinant
HEXIM1.
Figure 7. Both nuclear and cytoplasmic HEXIM1 proteins associate
with RNA. (A) SDS PAGE and western blot analysis of Cdk9 and
HEXIM1 present in nuclear extract (nuc) and cytosol (cyto). (B)
Proteins in nuclear extract and cytosol were treated with or without
RNase A, separated by native gel electrophoresis ﬁrst and then
HEXIM1 was visualized by western blot analysis. (C) Localization of
endogenous HEXIM1 by immunoﬂuorescence staining. The upper set
of micrographs shows DAPI staining of DNA and background
ﬂuorescence due to just the secondary antibody used. The second set
shows DAPI staining of DNA and the signal from aﬃnity-puriﬁed anti-
HEXIM1 antibodies using the same exposure time as that used for the
secondary antibody alone. (D) Isolation of HEXIM1-bound RNAs and
examination of RNA by northern blot analysis. Details are found in
the Materials and methods section.
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incubation with aﬃnity-puriﬁed anti-HEXIM1 antibodies,
while a signiﬁcant portion of 7SK but not U2 or U6 was
pulled down by aﬃnity-puriﬁed anti-HEXIM1 antibodies
(Figure 7D). This reinforces the observation that 7SK is
a HEXIM1-binding protein in vivo, and demonstrates a
successful isolation of HEXIM1-bound RNAs. Next,
we examined if microRNAs could be detected in
HEXIM1-bound RNAs. One microRNA, mir-16-1, was
chosen because it is a relatively abundant microRNA
species in HeLa cells (39). As shown in Figure 7D,
about half of the total mir-16-1 was pulled down by
aﬃnity-puriﬁed anti-HEXIM1 antibodies. It is possible
that the fraction of mir-16-1 associated with HEXIM1 is
a double-stranded intermediate and that the unbound
mir-16-1 is the mature single-stranded microRNA that
would be associated with a RISC complex and unavailable
to bind to HEXIM1. Although it might be expected that
pre-mir-16-1 RNA (89nt) would bind to HEXIM1 based
on its content of double-stranded regions, it was
not detected in this study. This could have been due to
its low abundance or the presence of other, more speciﬁc
mir-16-1-binding proteins.
DISCUSSION
In this article, we demonstrated that HEXIM1 is a
dsRNA-binding protein, and this interaction is indepen-
dent of RNA composition. Although dsDNA could
interact with HEXIM1, dsRNA exhibited at least
100-fold higher aﬃnity. We also provided evidence that
dsRNA, but not dsDNA, binding induced a large
conformational change in HEXIM1, which allows it to
recruit P-TEFb. Signiﬁcantly, P-TEFb kinase activity was
inhibited in this complex. Furthermore, we showed that
endogenous HEXIM1 localized in both cytoplasm and the
nucleus, and the majority of HEXIM1 in both locations
was generally associated with RNA.
Several previous studies have analyzed the potential
secondary structure of 7SK and the regions that support
association with HEXIM1. In an extensive analysis of
7SK sequences required for association of HEXIM1 and
P-TEFb in HeLa cells, Egloﬀ et al. found that many
mutations within the ﬁrst 100nt of 7SK resulted in the loss
of HEXIM1 binding (40). Their mutations were based on
a structure proposed in a previous study (41) that mapped
chemical and nuclease sensitivities of 7SK RNA and 7SK
RNPs pulled out of cells. In that study, most of the results
supported the proposed structure, but several sites of
moderate modiﬁcation (for example, U28, U30 and U66)
were inexplicably found embedded in stems, not loops, as
predicted from the known function of the modiﬁcation
reagents used (41). If mFold is used to predict
the secondary structure of the ﬁrst 100nt of 7SK,
two diﬀerent structures are predicted that have similar
thermodynamic stability (Supplementary Figure 1). One
(G¼ 40.06kcal/mole) is very similar to that proposed
by Wasserman and Steitz, and the other
(G¼ 40.37kcal/mole) is completely diﬀerent. In the
slightly more stable second structure, U28, U30 and U66
are present in two prominent loops instead of stems.
The complete chemical and nuclease sensitivity data
would be accommodated, if the isolated 7SK RNP
contained a mixture of the two structures. The structure
predicted for 7SK 10–48 used in our study is present in the
alternative structure predicted for the entire 1–100nt of
7SK (compare Figure 1 with Supplementary Figure 1).
Our results clearly demonstrate that HEXIM1 can bind to
7SK 10–48 or other short dsRNAs in vitro. However,
determination of what 7SK structure is present when
HEXIM1 and P-TEFb are associated in vivo will require
chemical modiﬁcation analysis of the RNA in 7SK RNPs
pulled down with antibodies to HEXIM1 or P-TEFb.
Here, we demonstrated that dsRNA can functionally
replace 7SK in vitro, and that most HEXIM1 is associated
with RNAs in vivo, yet in cells, 7SK is the only identiﬁed
RNA that allows formation of a complex with both
HEXIM1 and P-TEFb. A small stem and loop near the
30 end of 7SK has been shown to be essential for P-TEFb
association in vivo (40). However, our results indicate that
that region of 7SK is not needed in vitro and, in fact, that
no region of 7SK is needed for the dsRNA-dependent
conformational change that results in recruitment and
inhibition of P-TEFb. Because the two studies measured
HEXIM1 and P-TEFb binding under very diﬀerent
conditions, the results are not contradictory. However,
they suggest an interesting possibility. There could be a
modiﬁcation in HEXIM1, for example in its P-TEFb
interaction domain, which prevents it from interacting
with P-TEFb even when bound with RNAs. This
modiﬁcation would not be present on the recombinant
HEXIM1 utilized for the in vitro experiments here, but
could be present on the endogenous HEXIM1. A factor
associated with the 30 end of 7SK, but not other
RNAs, could be responsible for removing this negative
modiﬁcation from HEXIM1, thereby allowing only
7SK HEXIM1 but not other RNA HEXIM1 complexes
to recruit P-TEFb.
The ﬁnding that HEXIM1 is a dsRNA-binding protein
is surprising because 7SK has been previously regarded
as the only RNA associated with HEXIM1. Although
dsDNA could interact with HEXIM1 (Figure 2A),
this interaction can be readily displaced by dsRNA
(Figure 3C). On the contrary, dsRNA HEXIM1 interac-
tion is very stable and cannot be disrupted by dsDNA
(Figure 3B). Our results demonstrate that HEXIM1
prefers to bind A-form nucleic acids, and also suggest
that dsDNA HEXIM1 interaction may not be physiolog-
ically relevant. Our unpublished data indicated that
the minimal length of dsRNA for HEXIM1 interaction
is 12bp. However, there are no uninterrupted helices of
410nt in 7SK and 7SK (10–48) (Figure 1B). Taking
into consideration that HEXIM1 is a dimer with
two RNA-interaction regions (32,35) and HEXIM1
monomer does not bind RNA (data not shown), each
HEXIM1 RNA-interaction region may bind a short
stretch of dsRNA, and the distance between the two
RNA-interaction regions has to be at least the length of
a 12-bp dsRNA. It is not clear if structures in between
the two short stretches of dsRNA regions contribute
signiﬁcantly to the dsRNA HEXIM1 interaction.
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the previous hypothesis that RNA binding induces
a conformational change in N-terminal self-inhibitory
domain of HEXIM1 (32,33). The ﬁrst line of evidence
came from the observation that dsRNA reduced
the mobility of HEXIM1 dramatically. There are
two major determinants for a protein’s mobility on a
native gel, i.e. its overall negative charges and its shape.
More negative charges and a compact conformation
would give rise to a faster migration than a less negative
charged and extended conformation. Considering that
the overall negative charge of the dsRNA HEXIM1
complex is increased signiﬁcantly, one would expect
that the mobility of HEXIM1 should increase. Instead,
dsRNA HEXIM1 showed slower mobility than
HEXIM1, suggesting that it adapts a more expanded
conformation. In fact, HEXIM2 (21,22,35), a HEXIM1
homolog that has a much shorter N-terminal domain, but
otherwise shares high sequence identity with HEXIM1,
showed increased mobility upon dsRNA binding (data not
shown). The second line of evidence came from a large
decrease in intrinsic tryptophan ﬂuorescence and a slight
shift of the emission peak upon dsRNA, but not dsDNA
binding. Although a decrease in intrinsic ﬂuorescence
could be caused by the quenching of tryptophan
ﬂuorescence by nucleic acids, only dsRNA, but not
dsDNA, reduced the intrinsic ﬂuorescence of HEXIM1
dramatically. In addition, only dsRNA, but not dsDNA,
caused a shift of the emission wavelength. This is
consistent with the observation, obtained from the
native gel analysis, that only dsRNA but not dsDNA,
reduces the mobility of HEXIM1 dramatically. Taking all
the evidence into account, it is likely that, upon dsRNA
binding, there is a conformational change in HEXIM1
that exposes the P-TEFb-binding site.
Another interesting observation is that after RNase A
treatment, both cytoplasmic and nuclear HEXIM1
migrated the same as the recombinant HEXIM1 protein
on a native gel. Recombinant HEXIM1 has been shown to
be a dimer (32) under the same condition. Therefore,
endogenous HEXIM1 is likely to be a dimer as well. The
calculated molecular weight for a HEXIM1 dimer is
80kDa. However, biophysical studies estimated that
endogenous HEXIM1, free of 7SK and P-TEFb, has a
size of 95–130kDa (35). Our observation that most
endogenous HEXIM1 has RNAs associated could explain
this apparent discrepancy.
dsRNA-binding proteins are involved in a variety
of cellular processes such as RNA editing, RNAi,
viral defense and transcription (42). Unlike most
dsRNA-binding proteins, HEXIM1 lacks the character-
istic 50–100 amino acid dsRNA-binding motif (dsRBM).
The RNA-binding ability of HEXIM1 largely depends on
KHRR (amino acids 152–155). On the other hand, like
most, if not all, characterized dsRNA-binding proteins,
HEXIM1 binds to any dsRNA, regardless of its primary
sequence in vitro. Given this, a dsRNA substrate of one
dsRNA-binding protein could easily be bound by other
dsRNA proteins in the cell, resulting in crosstalk between
diﬀerent dsRNA-mediated pathways. However, some
dsRNA-binding proteins do recognize speciﬁc dsRNA
substrates in cells, and how this speciﬁcity is achieved
remains elusive (42–44). Our results do not at present
demonstrate conclusively that HEXIM1 is involved in
cellular processes other than controlling P-TEFb.
However, future studies including the identiﬁcation
of other HEXIM1-bound RNAs may shed light on the
function of the HEXIM1 RNA complexes found in
the cytoplasm and the nucleus.
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